AstraZeneca antibody cocktail fails to prevent COVID-19 symptoms in trial
Fox News
AstraZeneca’s antibody cocktail failed to prevent COVID-19 symptoms in trial participants recently exposed to the virus, the company announced Monday.
Overall, the company said AZD7442 was found to reduce the risk of developing symptomatic COVID-19 by 33% compared to placebo, "which was not statistically significant." However, the research team was encouraged by results pertaining to patients in the trial who were already infected with COVID-19 at the time of dosing, and said analysis is ongoing.More Related News